CYH vs SPRY
CYH: A large US hospital operator managing regional health networks and diverse outpatient care facilities across multiple states. SPRY: ARS Pharmaceuticals has developed neffy, the first FDA-approved needle-free intranasal epinephrine spray for the emergency treatment of severe allergic reactions.
Side-by-side fundamentals
| Metric | CYH | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $2.40 | $3.38 | |
| Market cap | $338M | $336M | |
| P/E as of 2026-10-30 | 9.60 | n/a | |
| Net margin FY2025, SEC XBRL | +4.1% | -203.3% | CYH higher |
| Operating margin FY2025, SEC XBRL | +11.9% | -212.9% | CYH higher |
| ROE FY2025, SEC XBRL | n/a | -149.9% | |
| ROA FY2025, SEC XBRL | +3.9% | -52.3% | CYH higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 7.73 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -1.2% | -5.5% | CYH higher |
| Revenue CAGR (3y) SEC XBRL | +0.7% | +300.1% | SPRY higher |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | CYH higher |
| Beta as of 2026-09-03 | 1.12 | 1.02 | |
| 1-year return as of 2026-10-30 close | -41.9% | -60.8% | CYH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.